Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763681 | 0.88 | KMT2A (0.42) | TRPM8KMT2AALDH1A1MEN1ADRA1A | |
| SCHEMBL3764668 | 0.87 | HPGD (0.49) | ALDH1A1HPGDMAPTHCRTR1HCRTR2 | |
| SCHEMBL3765281 | 0.86 | CHEK1 (0.47) | TRPM8KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL3758759 | 0.85 | KMT2A (0.50) | TRPM8KMT2AALDH1A1MEN1ADRA1D | |
| SCHEMBL3759975 | 0.81 | TRPM8 (0.37) | TRPM8KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL3761229 | 0.77 | SMN1; SMN2 (0.40) | KMT2AALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL3759347 | 0.77 | ALDH1A1 (0.41) | ALDH1A1HPGDMAPTSMN1; SMN2PDE10A | |
| SCHEMBL3761439 | 0.76 | TSHR (0.51) | TRPM8KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL3761415 | 0.74 | BCAT2 (0.46) | KMT2AALDH1A1MEN1HPGDMAPT | |
| SCHEMBL3769036 | 0.74 | GAA (0.41) | ALDH1A1HPGDMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | TRPM8 1034/4885KMT2A 2175/4885ALDH1A1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.